SCOTTSDALE, Ariz., Jan. 21 /PRNewswire-FirstCall/ -- ITL Laboratories, L.L.C. ("ITL") is planning a clinical trial to determine the effectiveness of a stem cell treatment for stress urinary incontinence. A recent clinical trial by Austrian researchers has demonstrated the potential usefulness of expanded muscle stem cell injections in the treatment of urinary incontinence. ITL plans to use its proprietary stem cell expansion technology to expand patients own muscle stem cells to treat stress urinary incontinence -- a condition that affects almost 15 million people (primarily women) worldwide. The condition occurs when the urethra narrows or otherwise becomes abnormal, or when the sphincter muscles that help open and close the urethra become weak or diminished, causing urine leakage when an individual exercises, coughs, sneezes, laughs or lifts heavy objects.
The cells used in the trial are not controversial because they are generated from the patient's own body. The treatment, which addresses the underlying problem of urinary incontinence, is believed to be one of the first stem cell therapies to enter clinical practice.
The trial is expected to begin in the summer of 2005 after the company establishes its offshore laboratory and medical clinic.
EpiPharma, Inc. ("EpiPharma") (Pink Sheets: EPHM) announced on January 18, 2005 that it has entered into an agreement to purchase 25% of ITL, an entity engaged in the research, development and administration of adult stem cells, including human umbilical cord stem cells (USCs) for the treatment of neurological and degenerative diseases.
EpiPharma was formed on September 13th, 2001 as a subsidiary of Baywood International, Inc. ("Baywood") (BULLETIN BOARD: BYWD) and began trading on the Pink Sheets on December 14, 2004. A letter of intent to acquire Aidan Products, L.L.C. ("Aidan") was originally signed by Baywood on May 19, 2004 and was renewed and transferred to EpiPharma on January 17, 2005. EpiPharma may immediately exercise its option to invest in ITL upon the close of the acquisition of Aidan. EpiPharma will remain as a majority-owned subsidiary of Baywood after the proposed transaction to acquire Aidan and the investment in ITL is completed.
EpiPharma, Inc. (Pink Sheets: EPHM) focuses on the development, production and acquisition of complex nutraceuticals and other novel technologies for therapeutic applications. EpiPharma's current objective is to sell these complex nutraceutical products through healthcare practitioners and to administer its novel technologies through other healthcare channels. Contact EpiPharma, Inc. at 1-800-519-2037 or for more information visit http://www.epipharma.com/.
Baywood International, Inc. (BULLETIN BOARD: BYWD) is a nutraceutical company specializing in the development, marketing and distribution of its own proprietary brands under the names Baywood PURECHOICE(R), Baywood SOLUTIONS(R) and Complete La Femme(R). The Company's products are distributed through independent and chain health food stores, pharmacies, grocery stores, and other direct-to-consumer channels both internationally and domestically. Contact Baywood International, Inc. at 1-888-350-0799 or for more information visit http://www.bywd.com/.
This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. The Issuer's expectations among other things are dependent upon general economic conditions, continued demand for its products, the availability of raw materials, retention of its key management and operating personnel, as well as other uncontrollable or unknown factors which are more fully disclosed in Baywood's Form 10-KSB's and 10-QSB's on file with the United States Securities and Exchange Commission.
CONTACT: Neil Reithinger, President of EpiPharma, Inc., +1-800-519-2037,firstname.lastname@example.org; or Sandy Rossen of I.R. International Consultants, Inc.,+1-516-816-2563, email@example.com, for EpiPharma, Inc.